Print Icon

Remember to add us to your contacts list to ensure you receive our emails

Hello and welcome to another fascinating edition of the EMJ Dermatology newsletter, your trusted source for all of the latest news and developments in the field. Within you will find a wealth of information, delivered in a concise and easy-to-digest format that is perfectly suited to the conscientious modern medical professional. As we move closer to autumn we will also experience the 24th EADV Congress, this year to be held in Copenhagen, Denmark. We have details on this and a selection of other upcoming events included for your perusal. We also present reports on some of the emerging dermatological technology making headway in the industry, such as a new device capable of performing skin biopsies quickly and without the need for anaesthetic, and the development of devices and dressings that may allow wounds to heal more quickly through electrical stimulation. We hope this newsletter proves to be both informative and enjoyable, and we wish you all the best until our next edition.


and Methylchloroisothiazolinone: New Insights

AR Rodrigues-Barata, L Conde-Salazar

Methylisothiazolinone (MI), along with Kathon™ CG (methylchloroisothiazolinone/MI), are widely used preservatives to prevent bacterial overgrowth in aqueous solutions of various types of cosmetic, household, and industrial products. Because of its high sensitising power and widespread use, MI is currently one of the most common causes of allergic contact dermatitis, both in our private lives and in the occupational field. As it was thought that MI had less sensitivity capacity, it started to be commercialised separately, and a new epidemic of sensitisation to these preservatives has been observed in recent years. MI should be included separately in the standard patch testing series. Also, the use of isothiazolinones should be revised, and legislative measures from the competent authorities should be implemented in order to resolve this problem.

PA Gerber, S Hilton
Quality-switched (q-switched) laser systems are the gold standard for the treatment of benign pigmented lesions and tattoo removal. A frequently used system is the q-switched ruby laser that emits monochromatic light at the wavelength of 694 nm. This system is used for the removal of age spots (senile lentigines), seborrhoeic keratosis, tattoos, and other dyschromatoses. The increasing need for the removal of, for example, age spots and unwanted tattoos, reflects both the wish of our ageing society to preserve a youthful appearance and the steadily growing prevalence of tattoos. This review highlights the potential, limitations, and novel treatment concepts of using q-switched ruby laser systems.

News Updates

“[This new device would] make it possible for the patient to leave the doctor's office with the diagnostic tests already done, and to begin earlier treatment if necessary.”

New Paradigm For Chronic Wounds Through Electrical Stimulation

"When used in acute and chronic wounds, bandages are essentially just a covering. With this technology we hope that the dressings will be able to make a significant functional contribution to healing the wounds and getting the patient back to full health as quickly as possible."


What’s Happening in EMJ: Dermatology

Here at EMJ, we have been working tirelessly to bring you the next edition of our eJournal, EMJ Dermatology 3.1, released this November which, along with the usual cutting-edge scientific papers, will include an exhaustive review of the EADV Congress, including reports on the foremost presentations and talking points, as well as interviews, abstract summaries, and news stories. It is surely not to be missed. Primarily EMJ is a platform for the exchange of ideas, so why not join the conversation at one or more of our social media outlets, which include Facebook, Twitter, and LinkedIn, or you can visit our website here.

Featuring a full review of EADV 2014





EMJ Dermatology 3.1

Inside review of
EADV 2015
Available November


European Medical Journal 

Head Office – The MedBIC, Anglia Ruskin University, Alan Cherry Drive, Chelmsford, Essex, CM1 1SQ

Sales Office Coppergate House, 16 Brune Street, London, E1 7NJ 

Switchboard: +44 (0) 1245 334450 

Registration No: 08198092. The information contained in this message is confidential and maybe legally privileged. It is intended for the addressee(s) only. Any unauthorised use, dissemination of the information, or unauthorised copying/forwarding of this message is prohibited. If you are not the intended addressee, please notify the sender immediately by return email and delete this message. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorised to state them.


To ensure that you continue receiving our emails, please add us to your address book or safe list. If you are receiving this email continuously and if you think this is SPAM, please report to and we will try our best to resolve your concerns. If you would like to Subscribe to receive further updates from the European Medical Journal, please follow the link at the bottom through to our automated system, alternatively if you would like to Unsubscribe please also use the link provided.